PV-10 Effective Against Melanoma

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled “Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.

To view Multimedia News Release, go to http://www.prnewswire.com/mnr/pvct/37868/

1. By: MultiVu
2. Categories News & Events
3. Views 117
4. Added :01-Jun-09
   Report This Video